Exploratory Clinical Trials of Investigational Agents for Neurological Disorders
National Institutes of Health
Description
This grant helps small businesses perform early-stage clinical trials for new treatments targeting neurological disorders. Successful applicants will receive support through the NeuroNEXT network, including coordination and data management assistance, along with help for recruiting and retaining participants at clinical sites.
This funding opportunity supports small businesses in conducting exploratory clinical trials for investigational agents related to neurological disorders. Successful applicants will gain access to the NeuroNEXT infrastructure, which includes support from the Clinical Coordinating Center and Data…
Source
Grant ID
PAR-25-133
Agency
National Institutes of Health
Subcategory/Subagency
National Institute of Neurological Disorders and Stroke
Key Dates
Application Window Closes
September 5, 2027
Opportunity Released
November 12, 2024
Open for Submission
November 12, 2024
Submission Deadline
September 5, 2027
Eligibility
The following categories of applicants are invited to apply:
- United States Small Business Concerns (SBCs) – for‑profit, with a U.S. place of business, operating primarily in the U.S. or contributing to the U.S. economy; including affiliates, have no more than 500 employees
- U.S. SBCs majority‑owned and controlled (>50%) by one or more U.S. citizens or permanent resident aliens; by other qualifying small businesses similarly owned; by an Indian tribe, Alaska Native Corporation (ANC), or Native Hawaiian Organization (NHO); or any combination of these (SBIR/STTR ownership pathway)
- U.S. SBCs majority‑owned (>50%) by multiple venture capital operating companies (VCOCs), hedge funds, or private equity firms (SBIR‑only), provided no single such firm owns >50% unless that firm itself qualifies as a U.S. SBC majority‑owned and controlled by U.S. individuals
- Joint ventures of eligible SBCs (each JV partner must independently meet an SBIR ownership pathway; and in any JV, foreign business entities must hold <50% participation)
Similar opportunities
- Limited Competition: Renewal Applications for NINDS-supported Clinical Trial Cooperative Agreement Awards (U01)
National Institutes of Health
- Notice of Funding Opportunity (NOFO) for Multi-Center Clinical Trials in Neurological Emergencies
National Institutes of Health
- Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
National Institutes of Health
- Investigator-Initiated Multisite Clinical Trials of Complementary and Integrative Health Approaches
National Institutes of Health
- NEI UG1 Cooperative Agreement for Clinical Trials
National Institutes of Health